Stockscreener 앱 받기
0.59
0.27%
0.0016
시장 영업 전:
.60
0.01
+1.69%
전일 마감가:
$0.5884
열려 있는:
$0.5784
하루 거래량:
67,424
Relative Volume:
0.02
시가총액:
$3.89M
수익:
-
순이익/손실:
$-10.31M
주가수익비율:
-0.2531
EPS:
-2.3308
순현금흐름:
$-6.32M
1주 성능:
+0.15%
1개월 성능:
+9.26%
6개월 성능:
-52.03%
1년 성능:
-55.30%
1일 변동 폭
$0.5701
$0.605
1주일 범위
$0.54
$0.6068
52주 변동 폭
$0.4111
$2.34
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Compare GLMD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
0.59 | 3.89M | 0 | -10.31M | -6.32M | -2.3308 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-05-22 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | 개시 | Craig Hallum | Buy |
| 2020-01-30 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-12-02 | 개시 | Canaccord Genuity | Buy |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-08-02 | 재확인 | Maxim Group | Buy |
| 2018-07-13 | 개시 | Stifel | Buy |
| 2018-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-06-12 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2018-02-14 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-15 | 개시 | ROTH Capital | Buy |
| 2017-08-08 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 재확인 | Maxim Group | Buy |
| 2016-08-01 | 재확인 | Maxim Group | Buy |
| 2016-07-06 | 재개 | ROTH Capital | Buy |
| 2016-03-28 | 재개 | H.C. Wainwright | Buy |
| 2015-06-23 | 개시 | H.C. Wainwright | Buy |
| 2015-05-06 | 개시 | Sun Trust Rbsn Humphrey | Buy |
모두보기
Galmed Pharmaceuticals Ltd 주식(GLMD)의 최신 뉴스
Tissue Dynamics, Galmed partner on cardiac fibrosis model By Investing.com - Investing.com Canada
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics - PR Newswire
Tissue Dynamics and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announce a strategic collaboration to jointly develop a chronic cardiac fibrosis research platform focused on human disease models. - Bitget
GLMD (Galmed Pharmaceuticals Ltd. Ordinary Shares) posts wider than expected Q4 2025 loss, shares dip nearly one percent.Meet Estimates - Xã Thanh Hà
Shmuel Nir Net Worth (2026) - GuruFocus
Amir Poshinski Net Worth (2026) - GuruFocus
Brueck Liat Nissimov Net Worth (2026) - GuruFocus
Doron Leib Cohen Net Worth (2026) - GuruFocus
Allen Baharaff Net Worth (2026) - GuruFocus
Yohai Stenzler Net Worth (2026) - GuruFocus
Guy Nehemya Net Worth (2026) - GuruFocus
Galmed Pharmaceuticals (GLMD) Stock: Beginner's Guide (Smart Money Outflows) 2026-04-15Most Discussed Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Galmed Pharmaceuticals Ltd. and Ramot At Tel Aviv University Enter Research Collaboration Agreement - marketscreener.com
Galmed partners with Tel Aviv University on brain cancer therapy By Investing.com - Investing.com Australia
Galmed partners with Tel Aviv University on brain cancer therapy - Investing.com
Galmed Pharmaceuticals Teams with Tel Aviv University on Aramchol for Metastatic Brain Cancer - TipRanks
Galmed (NASDAQ: GLMD) and Tel Aviv University test Aramchol for brain cancer - Stock Titan
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers - PR Newswire
GLMD SEC FilingsGalmed Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Galmed stock soars on brain-penetrating Aramchol formulation - MSN
Galmed Stock Soars On Brain-Penetrating Aramchol FormulationGalmed Pharmaceuticals (NASDAQ:GLMD) - Benzinga
Galmed Unveils Brain-Penetrant Aramchol Formulation, Expanding Flagship Drug Into CNS Diseases - TipRanks
Galmed Pharmaceuticals Maps Future with Aramchol Strategy - timothysykes.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol - The AI Journal
Is Galmed Pharmaceuticals (GLMD) Stock a Safe Investment | Price at $0.52, Down 1.03%Diversification - Newser
[EFFECT] Galmed Pharmaceuticals Ltd. SEC Filing - Stock Titan
Going concern doubts and funding limits in Galmed (NASDAQ: GLMD) 2025 20-F - Stock Titan
MEDIA ADVISORY – Minister LeBlanc, Secretary of State Long and Parliamentary Secretary Myles to highlight investments supporting the Canadian Armed Forces following achievement of the NATO 2% defence spending target - Weekly Voice
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - ChartMill
Ideas Watch: Is Galmed Pharmaceuticals Ltd stock a good dividend stock2026 Update & Entry and Exit Point Strategies - baoquankhu1.vn
Portfolio Update: Can Galmed Pharmaceuticals Ltd grow without dilution2026 Recap & Safe Entry Point Alerts - baoquankhu1.vn
GLMD Stock Price, Quote & Chart | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
Sectors Review: Can Galmed Pharmaceuticals Ltd deliver consistent dividendsMarket Rally & Low Risk Growth Stock Ideas - baoquankhu1.vn
Galmed (GLMD) director David Sidransky reports initial share and option holdings - Stock Titan
Galmed (GLMD) CFO details Ordinary Share, option and RSU holdings - Stock Titan
[Form 3] Galmed Pharmaceuticals Ltd. In... - Stock Titan
Galmed Pharmaceuticals (NASDAQ: GLMD) CAO reports shares, options and RSUs - stocktitan.net
Galmed Pharmaceuticals Ltd. (GLMD) CSO details option holdings - Stock Titan
Galmed (GLMD) director Amir Poshinski details shares, RSUs and options - Stock Titan
Galmed Pharmaceuticals (GLMD) director Nir Shmuel details initial share and RSU holdings - Stock Titan
Aug Chart Watch: Will Galmed Pharmaceuticals Ltd. stock maintain dividend yieldShort Setup & Advanced Swing Trade Entry Plans - Naître et grandir
Smart Money: Is Galmed Pharmaceuticals Ltd stock a good dividend stockMarket Growth Review & Reliable Price Breakout Signals - baoquankhu1.vn
Galmed Pharmaceuticals Shares Edge Higher Following CEO’s Positive Update - MSN
Galmed Pharmaceuticals Shareholders Approve Proposal at Special Meeting - The Globe and Mail
Galmed Pharmaceuticals (NASDAQ: GLMD) shareholders back proposal at March 5 special meeting - Stock Titan
Galmed Pharmaceuticals Adjourns Special Shareholder Meeting for Lack of Quorum - TipRanks
Galmed Pharmaceuticals (GLMD) adjourns shareholder meeting and resets date - Stock Titan
GLMD.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GLMD Should I Buy - Intellectia AI
Galmed Pharmaceuticals Ltd (GLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):